CNBCadded this to Health and ScienceFDA Pharmacy warns FDA of cancer-causing chemical found in widely used heart pillCNBC - Berkeley Lovelace Jr. A pharmacy warned the Food and Drug Administration that it found a chemical believed to cause cancer in a widely used blood pressure medication, …
Bloombergadded this to BloombergValsartan Fourth Carcinogen Discovered in Heart Pills Used by MillionsBloomberg - Anna Edney An online pharmacy told U.S. regulators it found another cancer-causing chemical in widely prescribed blood-pressure pills, raising new questions …
CBS Newsadded this to MoneyWatchValsartan Valsartan: Another cancer-causing chemical found in widely used blood-pressure medicationCBS News - Kate Gibson Online pharmacy Valisure has discovered another cancer-causing chemical in blood-pressure pills made by companies including Novartis, according to a …
Daily Mailadded this to Top StoriesFDAFOURTH carcinogen found in US blood pressure drugs as global pill-contamination scandal drags on - leaving millions at riskdailymail.co.uk - Mia De Graaf Health Editor A fourth carcinogen has been found in America's supply of blood pressure drugs. The US and Europe have faced severe shortages of heart medications …
Reutersadded this to Health & LifestyleValsartan Online pharmacy flags possible new impurity in blood pressure drugReuters - by Manojna Maddipatla in Bengaluru and Michael Erman in New York(Reuters) - Online pharmacy Valisure reported that it found a new cancer-causing impurity in some versions of widely prescribed blood pressure medicine valsartan, but U.S. regulators said on Tuesday that
Seeking AlphaInvesting Regeneron loses a bull as threats to Eylea riseSeeking Alpha - Liz Kiesche Argus Research analysts Jasper Hellweg and Kelly Hannigan see threats to Reneron Pharmaceuticals' (REGN +1.2%) main revenue driver, Eylea, prompting …
FlipboardIcon version of the Flipboard logoMedical Research Zolgensma: A Remarkable New Treatment, An ICER Analysis, And A Poorly Justified Pricehealthaffairs.org - Peter B. Bach Defects in both sets of alleles in the coding region for the survival motor neuron 1 (SMN1) protein lead to the rare heritable condition spinal …
AxiosGene Therapy $1.8 million gene therapy will be the 2nd-most expensive drug in the worldAxios - Bob Herman The price of Zynteglo, a new gene therapy made by Bluebird Bio to treat a rare genetic blood disorder, will be almost €1.6 million ($1.8 million) in …
PPeak Bggradded this to Biotech Investing VBI's hepatitis B vaccine meets primary goalsSeeking Alpha - Carl Surran VBI Vaccines (NASDAQ:VBIV) -21.1% pre-market after announcing a Phase 3 study testing its Sci-B-Vac hepatitis B vaccine against GlaxoSmithKline's …
Gene Therapy Novartis’ new $2.1 million drug has roots in Philadelphia. Here’s how the city has impacted treatment of rareinquirer.com - Sarah Gantz That’s the advice doctors gave Steve and Gina Cannady after diagnosing their 3-year-old daughter, Emma, with spinal muscle atrophy (SMA), a rare …
Greece Presence of mind requiredekathimerini.com - Editorial The allegations made by Deputy Supreme Court Prosecutor Ioannis Angelis over government involvement in the Novartis case – coming after similar …
Greece Novartis probes, justice appointments tax governmentekathimerini.com - Costis P. Papadiochos As investigations get under way into claims by a top prosecutor that a government official sought to influence a probe into an alleged bribery …
Medicine Do You Consider Cost When Prescribing a Drug?medscape.com - www.medscape.com The US Food and Drug Administration recently approved onasemnogene abeparvovec-xioi (Zolgensma, AveXis Inc, a Novartis company), the first gene …
Times Nowadded this to Times Now Novartis India appoints Sanjay Murdeshwar as vice chairman and managing directortimesnownews.com - PTI Board of Directors of Novartis India Ltd at their meeting held today, have approved the appointment of Sanjay Murdeshwar as Vice Chairman & Managing …
Seeking AlphaInvesting VEA As Good As Any Developed Markets Ex-U.S. ETFSeeking Alpha - Strubel Investment Management The Vanguard FTSE Developed Markets ETF (VEA) is one of the best ETFs available for gaining exposure to the developed market. It's among the cheapest …
CNBCGene Therapy Bluebird Bio CEO defends $1.8 million price for gene therapy — 'It's really thinking about it differently'CNBC - Berkeley Lovelace Jr. Bluebird Bio CEO Nick Leschly on Friday defended the biotech company's $1.8 million price tag for its new gene therapy to treat a rare genetic blood …
The Wall Street Journal.added this to BusinessGene Therapy New Gene Therapy Priced at $1.8 Million in EuropeThe Wall Street Journal. - Jonathan D. RockoffA new gene therapy for a rare blood disorder will sell for €1.6 million ($1.8 million) in Europe, according to the maker of the recently approved treatment, whose sticker price is the latest indication
Greece Corruption prosecutor charges four in Novartis inquiryekathimerini.com - info@kathimerini.gr Corruption prosecutor Eleni Touloupaki on Friday brought charges of money laundering and bribing a politician against four unidentified suspects in …
Gene Therapy Pharmalittle: Bluebird Bio prices gene therapy at $1.8 million; lawmakers urge feds to step up generic probestatnews.com - Ed Silverman • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and …
Greece A crisis in our justice systemekathimerini.com - Nikos Konstandaras Greek society is plagued by a general sense of injustice and this malaise is the cause of many ills. Our democracy provides us with freedoms that …
Medicine The top 10 most-expensive meds in the U.S.—and they're not the usual suspectsfiercepharma.com - Eric Sagonowsky Two new gene therapies—from Novartis and Spark Therapeutics—carry price tags higher than any other drugs in the U.S., elbowing aside the brands we've …
Barron'sadded this to Barron'sInvesting A Stock Fund Challenges the Definition of Growth. It’s Paying Off.Barron's - Reshma Kapadia Elisa Mazen got her start in junk. High-yield debt was the place to be in the 1980s, amid a leveraged buyout and takeover boom. “It had all the …
PPeak Bggradded this to Biotech InvestingInvesting Novartis Makes Substantial Pipeline Progress On A Couple Of FrontsSeeking Alpha - Terry Chrisomalis Novartis (NVS) announced that it had successfully completed a phase 3 study treating patients with asthma using QMF149. These positive phase 3 …
SFChronicleadded this to Tech ChronicleCRISPR GlaxoSmithKline to fund $67 million of CRISPR research at UCsfchronicle.com - Catherine Ho The University of California announced a major deal Thursday with the drug company GlaxoSmithKline, in which the pharmaceutical firm will provide up …
Greece New twist in Novartis affair as prosecutor implicates gov't officialekathimerini.com - Ioanna Mandrou In the wake of his claims that judicial officials mismanaged and skewed the Novartis bribery probe, Deputy Supreme Court Prosecutor Ioannis Angelis …
Seeking AlphaInvesting Phase 1 study of Xoma's gevokizumab underwaySeeking Alpha - Douglas W. House XOMA (NASDAQ:XOMA) announces that licensee Novartis (NYSE:NVS) has launched a Phase 1 clinical trial evaluating gevokizumab, an anti-IL1β monoclonal …
PPeak Bggradded this to Biotech InvestingArthritis Novartis' Cosentyx shows sustained benefit in late-stage psoriatic arthritis studySeeking Alpha - Douglas W. House New data from a Phase 3 clinical trial, FUTURE 5, evaluating Novartis' (NYSE:NVS) Cosentyx (secukinumab) in adults with active psoriatic arthritis …
Greece ND says prosecutor's claims confirm Novartis case is a 'frame-up'ekathimerini.com - info@kathimerini.gr The main opposition said on Wednesday that the allegations made by a deputy Supreme Court prosecutor on the Novartis case proves that the probe was a …
Greece Novartis prosecutors face inquiryekathimerini.com - Ioanna Mandrou In the latest twist in the complex investigation into the Swiss pharmaceutical firm Novartis and whether Greek politicians accepted bribes to boost …
Bloombergadded this to BloombergUnited States Novartis's Secret Settlement Talks Revealed in Accidental FilingBloomberg - Chris Dolmetsch Confidential settlement talks between Novartis AG and the U.S. government over allegations that the company paid doctors to market its products are …
